| pubmed-article:10912577 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10912577 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:10912577 | lifeskim:mentions | umls-concept:C0877373 | lld:lifeskim |
| pubmed-article:10912577 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:10912577 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:10912577 | lifeskim:mentions | umls-concept:C0123931 | lld:lifeskim |
| pubmed-article:10912577 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:10912577 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:10912577 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:10912577 | pubmed:dateCreated | 2000-8-8 | lld:pubmed |
| pubmed-article:10912577 | pubmed:abstractText | Based on preclinical data demonstrating synergy between camptothecin analogues and taxanes, we determined the maximum tolerated dose (MTD) of irinotecan that could be given in combination with a fixed dose of paclitaxel of 75 mg/m2, when both drugs were delivered on a weekly schedule. The pharmacokinetics of this combination were explored to determine whether the sequence of administration affected the elimination of irinotecan. | lld:pubmed |
| pubmed-article:10912577 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10912577 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10912577 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10912577 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10912577 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10912577 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10912577 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10912577 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10912577 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10912577 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10912577 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10912577 | pubmed:issn | 0344-5704 | lld:pubmed |
| pubmed-article:10912577 | pubmed:author | pubmed-author:ChengYY | lld:pubmed |
| pubmed-article:10912577 | pubmed:author | pubmed-author:LULL | lld:pubmed |
| pubmed-article:10912577 | pubmed:author | pubmed-author:MurrenJ RJR | lld:pubmed |
| pubmed-article:10912577 | pubmed:author | pubmed-author:PizzornoGG | lld:pubmed |
| pubmed-article:10912577 | pubmed:author | pubmed-author:DiStasioS ASA | lld:pubmed |
| pubmed-article:10912577 | pubmed:author | pubmed-author:McKeonAA | lld:pubmed |
| pubmed-article:10912577 | pubmed:author | pubmed-author:BurtnessB ABA | lld:pubmed |
| pubmed-article:10912577 | pubmed:author | pubmed-author:LeffertJ JJJ | lld:pubmed |
| pubmed-article:10912577 | pubmed:author | pubmed-author:PeccerilloKK | lld:pubmed |
| pubmed-article:10912577 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10912577 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:10912577 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10912577 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10912577 | pubmed:pagination | 43-50 | lld:pubmed |
| pubmed-article:10912577 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:10912577 | pubmed:meshHeading | pubmed-meshheading:10912577... | lld:pubmed |
| pubmed-article:10912577 | pubmed:meshHeading | pubmed-meshheading:10912577... | lld:pubmed |
| pubmed-article:10912577 | pubmed:meshHeading | pubmed-meshheading:10912577... | lld:pubmed |
| pubmed-article:10912577 | pubmed:meshHeading | pubmed-meshheading:10912577... | lld:pubmed |
| pubmed-article:10912577 | pubmed:meshHeading | pubmed-meshheading:10912577... | lld:pubmed |
| pubmed-article:10912577 | pubmed:meshHeading | pubmed-meshheading:10912577... | lld:pubmed |
| pubmed-article:10912577 | pubmed:meshHeading | pubmed-meshheading:10912577... | lld:pubmed |
| pubmed-article:10912577 | pubmed:meshHeading | pubmed-meshheading:10912577... | lld:pubmed |
| pubmed-article:10912577 | pubmed:meshHeading | pubmed-meshheading:10912577... | lld:pubmed |
| pubmed-article:10912577 | pubmed:meshHeading | pubmed-meshheading:10912577... | lld:pubmed |
| pubmed-article:10912577 | pubmed:meshHeading | pubmed-meshheading:10912577... | lld:pubmed |
| pubmed-article:10912577 | pubmed:meshHeading | pubmed-meshheading:10912577... | lld:pubmed |
| pubmed-article:10912577 | pubmed:meshHeading | pubmed-meshheading:10912577... | lld:pubmed |
| pubmed-article:10912577 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10912577 | pubmed:articleTitle | Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer. | lld:pubmed |
| pubmed-article:10912577 | pubmed:affiliation | Department of Medicine, Yale University School of Medicine and the Yale Cancer Center, New Haven, CT 06520, USA. | lld:pubmed |
| pubmed-article:10912577 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10912577 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:10912577 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:10912577 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
